Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow.

J Immunother Cancer · 2024 · PMC10806559 · PMID 38212119

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

7 However, patients with PD-L1 enrichment displayed a clear trend toward improved efficacy, especially those with CPS≥20 in the exploratory subgroup.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.